Ge GH, Ye Y, Zhou XB, Chen L, He C, Wen DF, Tan YW. Hepatitis B surface antigen levels of cessation of nucleos(t)ide analogs associated with virological relapse in hepatitis B surface antigen-negative chronic hepatitis B patients. World J Gastroenterol 2015; 21(28): 8653-8659 [PMID: 26229407 DOI: 10.3748/wjg.v21.i28.8653]
Corresponding Author of This Article
Yun Ye, Associate Professor, Department of Hepatosis, The Third Hospital of Zhenjiang Affiliated Jiangsu University, No. 300 Daijiamen, Runzhou Distinct, Zhenjiang 212000, Jiangsu Province, China. tyw915@sina.com
Research Domain of This Article
Gastroenterology & Hepatology
Article-Type of This Article
Retrospective Study
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Share the Article
Ge GH, Ye Y, Zhou XB, Chen L, He C, Wen DF, Tan YW. Hepatitis B surface antigen levels of cessation of nucleos(t)ide analogs associated with virological relapse in hepatitis B surface antigen-negative chronic hepatitis B patients. World J Gastroenterol 2015; 21(28): 8653-8659 [PMID: 26229407 DOI: 10.3748/wjg.v21.i28.8653]
World J Gastroenterol. Jul 28, 2015; 21(28): 8653-8659 Published online Jul 28, 2015. doi: 10.3748/wjg.v21.i28.8653
Hepatitis B surface antigen levels of cessation of nucleos(t)ide analogs associated with virological relapse in hepatitis B surface antigen-negative chronic hepatitis B patients
You-Wen Tan, Dan-Feng Wen, Cong He, Li Chen, Xin-Bei Zhou, Yun Ye, Guo-Hong Ge
Guo-Hong Ge, Yun Ye, Xin-Bei Zhou, Li Chen, Cong He, Dan-Feng Wen, You-Wen Tan, Department of Hepatosis, The Third Hospital of Zhenjiang Affiliated Jiangsu University, Zhenjiang 212000, Jiangsu Province, China
Author contributions: Ge GH and Ye Y wrote the manuscript; Chen L, Zhou XB and He C provided analytical tools and were involved in editing the manuscript; Weng DF provided all of the human material; Ye Y designed the study; and Tan YW provided support for this work.
Supported by Natural Science Foundation of Jiangsu Province, China, No. BK2011515; Medical Project of Health Department Jiangsu Province, No. H201248; Preventive Medicine research projects of Jiangsu Province, No. Y2012016; and the Social Development Project of Zhenjiang City, No. SH2013056.
Institutional review board statement: The study protocol was conducted within the guidelines of the 1975 Declaration of Helsinki and was approved by the ethics committee of The Third Hospital of Zhenjiang Affiliated Jiangsu University.
Informed consent statement: All study participants, or their legal guardian, provided informed written consent prior to study enrollment.
Conflict-of-interest statement: No potential conflicts of interest relevant to this article were reported.
Data sharing statement: No additional data are available.
Correspondence to: Yun Ye, Associate Professor, Department of Hepatosis, The Third Hospital of Zhenjiang Affiliated Jiangsu University, No. 300 Daijiamen, Runzhou Distinct, Zhenjiang 212000, Jiangsu Province, China. tyw915@sina.com
Telephone: +86-511-88925605 Fax: +86-511-88970779
Received: January 29, 2015 Peer-review started: January 30, 2015 First decision: March 10, 2015 Revised: March 26, 2015 Accepted: May 2, 2015 Article in press: May 4, 2015 Published online: July 28, 2015 Processing time: 181 Days and 13.4 Hours
Core Tip
Core tip: To study the rate of virological relapse in hepatitis B e antigen (HBeAg)-negative patients after stopping antiviral therapy. Two hundred and four patients were eligible for this analysis. The cumulative probability of virological relapse after stopping antiviral therapy was 79.41% (162/204) in 2 years and 43.82% (71/162) in 1 year. Cumulative probability of virological relapse in levels of the hepatitis B surface antigen (HBsAg) ≥ 1500IU/L group was higher than that of levels of the HBsAg < 1500 IU/L group. The cutoff value for predicting virological relapse was 1443 IU/L. We found that the virological relapse rate maintained a high level after stopping NUCs in HBeAg-negative patients and HBsAg levels of cessation of nucleos(t)ide analogs predicted virological relapse.
